Global Persistent Corneal Epithelial Defects Treatment Market is expected to grow at a substantial CAGR of 4.3% in the forecast period 2020 to 2027. The years considered for study are as mentioned below.
Access Full Report at https://www.databridgemarketresearch.com/reports/global-persistent-corneal-epithelial-defects-treatment-market
Global persistent corneal epithelial defects treatment market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased various strategic developments owing to favourable market scenario.
The major players dealing in global persistent corneal epithelial defects treatment market are introducing strong range of product portfolio. This has also helped the company to maximize the sales with enhanced product portfolio. For instance, In April 2019, Bausch Health launched LOTEMAX SM (Loteprednol Etabonate Ophthalmic Gel) 0.3 8% in the U.S. It is indicated for the treatment of pain following ocular surgery and postoperative inflammation. This launch will help to expand its wings in post-operative ocular inflammation/ pain in the market
Johnson & Johnson Services, Inc. is the dominating player in the persistent corneal epithelial defects treatment market, which is followed by Allergan, Bio-Tissue (A Subsidiary TissueTech, Inc.), Laboratoires THEA S.A.S, Integra LifeSciences Corporation, Novartis AG, Bausch Health. The other key players existing in the Skye Biologics Inc., I-MED Pharma inc., Almirall, S.A, Next Biosciences, Dompé Farmaceutici S.p.A, Kala Pharmaceuticals, Hunt Valley PharmaLAB, Ocular Science, Inc., Katena Products Inc. among others.
Johnson & Johnson Services, Inc:
Johnson & Johnson Services, Inc. is headquartered in New Jersey, U.S. was founded in 1886. The company is engaged in the research and development, manufacturing and sale of a wide range of products in the health care field. The company is providing product under contact lens products, ocular surface care, and surgical products category. The company is pharmaceutical, medical devices, consumer segments. The market focus product lies under life pharmaceutical, consumer segments. The company is continuously engaged in manufacturing and developments of persistent corneal epithelial defects treatment.
- In March 2019, Johnson & Johnson Vision Care, Inc. has announced that ACUVUE OASYS is now available with Transitions Light Intelligent Technology in the U.S. The new TRANSITIONS in ACUVUE OASYS will help company to increase its market share as the product is first-of-its-kind photochromic contact lens.
It has its global networks through direct sales representatives and distributors in Europe, Asia-Pacific, Middle East & Africa, and Americas through its subsidiaries in Johnson & Johnson Vision Care, Inc. (U.S.), Neutrogena (U.S.), DePuy Synthes (U.S.), Ethicon USA, LLC. (U.S.), Janssen Global Services, LLC (Belgium) among others
Allergan:
Allergan is headquartered in Dublin, Ireland was incorporated in 2013. The company is focused on developing, manufacturing and commercializing of various pharmaceutical, biologic, device, surgical and regenerative medicine products. The company is providing products under medical aesthetics, eye care, central nervous system, gastroenterology categories. The company is operating in US specialized therapeutics, US general medicine, International, Other segments. The market focus product lies under US specialized therapeutics segments. The company is continuously engaged in manufacturing and developments of persistent corneal epithelial defects treatment.
The company has wide global presence across the globe such as North America, South America, Europe, Asia-Pacific, Middle East and Africa. In addition to it, the company also generates its revenue from the various subsidiary companies such as ZELTIQ Aesthetics, Inc. (U.S.), Bonti, Inc. (U.S.), Allergan Medical (U.S.), Kythera Biopharmaceuticals, Inc. (U.S.), Oculeve, Inc. (U.S.) among others.
Bio-Tissue (A Subsidiary TissueTech, Inc.):
Bio-Tissue (A Subsidiary TissueTech, Inc.) has headquartered in Florida, U.S. The company focuses on the development of advanced wound care and ocular hygiene solutions for ocular diseases and disorders. The company is providing product under PROKERA, AmnioGraft, AmnioGuard, Cliradex brands. The Company engaged in business expansion through strategic agreement of persistent corneal epithelial defects treatment products.
- In October, Bio-Tissue entered in strategic agreement with Optima Pharmazeutische GmbH, a pharmaceutical company that offers ophthalmology, otorhinolaryngology and pneumology products. This agreement helps Bio-Tissue to distribute its Natural Ocular Cleanser in Germany.
The company has presence in U.S.
Recent Strategic Decisions
